McKesson Europe AG (CAKFY) — AI Stock Analysis

McKesson Europe AG provides pharmaceutical distribution and retail pharmacy services across Europe. As a subsidiary of McKesson Corporation, it operates through wholesale branches, distribution centers, and retail pharmacies, offering a range of healthcare products and services.

Company Overview

TL;DR:

McKesson Europe AG, a subsidiary of McKesson Corporation, is a major player in the European pharmaceutical distribution and retail pharmacy sectors. Operating through a network of wholesale branches, distribution centers, and retail pharmacies, the company provides pharmaceutical products, healthcare services, and pharmacy management solutions across multiple European countries.

About CAKFY

McKesson Europe AG, formerly known as Celesio AG, traces its roots back to 1835 and is headquartered in Stuttgart, Germany. The company changed its name in September 2017 after becoming a subsidiary of McKesson Corporation. McKesson Europe AG operates in the pharmaceutical and healthcare sectors, providing logistics and other services. It has two primary divisions: Pharmaceutical Distribution and Retail Pharmacy. The Pharmaceutical Distribution division is involved in the wholesale of pharmaceutical and healthcare products, serving approximately 40,000 pharmacies and hospitals through 90 wholesale branches and operating 70 distribution centers across Europe. The Retail Pharmacy division operates around 2,000 owned pharmacies and has approximately 8,000 members in its brand partnership program. This division provides outpatient drug, e-commerce, and home care services, primarily under the Lloyds Pharmacy brand in countries like Belgium, Ireland, Italy, and the United Kingdom. The division offers traditional prescription drugs, over-the-counter products, and medical services. McKesson Europe AG also provides services for pharmacists, including the organization and management of pharmacy cooperation programs in Great Britain, France, Portugal, and Belgium.

Investment Thesis

McKesson Europe AG presents a complex investment case. The company's extensive distribution network and retail pharmacy presence across Europe provide a stable revenue base. However, the company's negative profit margin of -0.5% and a high P/E ratio of -73.27 raise concerns about profitability. Growth catalysts include expanding e-commerce and home care services. Key risks include regulatory changes in the pharmaceutical industry and competition from other distributors. Investors should closely monitor the company's efforts to improve profitability and adapt to evolving market dynamics.

Industry Context

McKesson Europe AG operates in the competitive pharmaceutical distribution and retail pharmacy industry. The industry is characterized by increasing demand for healthcare services, driven by an aging population and rising prevalence of chronic diseases. Key trends include the growth of e-commerce and home care services, as well as increasing regulatory scrutiny. McKesson Europe AG competes with other major distributors and retail pharmacy chains, such as ABCZF (All American Healthcare Corp), ANHGY (Anthem Inc), ARHCF (Arches Health Care, Inc.), ASPHF (Aspen Healthcare Inc), and DCHPF (Direct Communication Healthcare).

Medical - Distribution

Healthcare

Growth Opportunities

Expansion of E-commerce and Home Care Services: McKesson Europe AG can capitalize on the growing demand for online pharmacy services and home healthcare. The e-commerce market in Europe is projected to reach $200 billion by 2028, offering a significant growth opportunity. By expanding its online platform and home care offerings, McKesson Europe AG can reach a wider customer base and increase revenue streams. Timeline: Ongoing.
Strategic Partnerships and Acquisitions: Forming strategic partnerships with healthcare providers and acquiring smaller pharmacy chains can expand McKesson Europe AG's market presence and service offerings. The company can leverage partnerships to offer integrated healthcare solutions and enhance customer loyalty. Timeline: Ongoing.
Development of Value-Added Services for Pharmacists: McKesson Europe AG can further develop and expand its services for pharmacists, such as pharmacy cooperation programs and management tools. By providing value-added services, the company can strengthen its relationships with pharmacists and increase its market share. Timeline: Ongoing.
Geographic Expansion within Europe: Expanding into new geographic markets within Europe can drive growth for McKesson Europe AG. By entering underserved markets or acquiring existing pharmacy chains, the company can increase its revenue and market share. Timeline: Ongoing.
Focus on Specialty Pharmaceuticals: The market for specialty pharmaceuticals is growing rapidly, driven by the development of new and innovative therapies. McKesson Europe AG can focus on distributing specialty pharmaceuticals and providing related services to capitalize on this trend. Timeline: Ongoing.

Operates approximately 2,000 owned pharmacies and supports 8,000 members in its brand partnership program, indicating a strong retail presence.
Serves approximately 40,000 pharmacies and hospitals through its 90 wholesale branches, showcasing a wide distribution network.
Profit Margin is -0.5%, indicating potential challenges in achieving profitability.
P/E ratio is -73.27, reflecting the company's current earnings situation.
Beta of 0.13 suggests low volatility compared to the overall market.

What They Do

Wholesale distribution of pharmaceutical products to pharmacies and hospitals.
Operation of retail pharmacies under the Lloyds Pharmacy brand.
Provision of outpatient drug services.
E-commerce services for pharmaceutical products.
Home care services.
Management of pharmacy cooperation programs.
Distribution of traditional prescription drugs and over-the-counter products.
Provision of medical services.

Business Model

Generates revenue through the wholesale distribution of pharmaceutical products.
Earns revenue from the operation of retail pharmacies and the sale of prescription and over-the-counter drugs.
Provides e-commerce services, generating revenue through online sales.
Offers home care services, generating revenue through service fees.

Pharmacies: Supplies pharmaceutical products to approximately 40,000 pharmacies.
Hospitals: Distributes pharmaceutical products to hospitals.
Individual Patients: Serves patients through its retail pharmacies and e-commerce platform.
Pharmacists: Provides services and support to pharmacists through its pharmacy cooperation programs.

Extensive Distribution Network: Operates a large network of wholesale branches and distribution centers across Europe.
Strong Retail Pharmacy Presence: Operates a significant number of retail pharmacies under the Lloyds Pharmacy brand.
Established Brand Reputation: Has a long history and established brand reputation in the European pharmaceutical market.
Part of McKesson Corporation: Benefits from the resources and expertise of its parent company, McKesson Corporation.

Catalysts

Ongoing: Expansion of e-commerce and home care services to drive revenue growth.
Ongoing: Strategic partnerships and acquisitions to expand market presence.
Ongoing: Development of value-added services for pharmacists to strengthen customer relationships.
Ongoing: Geographic expansion within Europe to increase market share.
Ongoing: Focus on specialty pharmaceuticals to capitalize on the growing market.

Risks

Ongoing: Increasing competition from other pharmaceutical distributors and retail pharmacy chains.
Potential: Pricing pressures from governments and healthcare providers.
Potential: Economic downturn in Europe affecting consumer spending on healthcare products.
Potential: Disruptions in the supply chain impacting the availability of pharmaceutical products.
Potential: Regulatory changes in the pharmaceutical industry impacting pricing and distribution.

Strengths

Extensive distribution network across Europe.
Strong retail pharmacy presence with the Lloyds Pharmacy brand.
Established relationships with pharmacies and hospitals.
Part of the global McKesson Corporation.

Weaknesses

Negative profit margin.
High P/E ratio.
Exposure to regulatory changes in the pharmaceutical industry.
Dependence on the European market.

Opportunities

Expansion of e-commerce and home care services.
Strategic partnerships and acquisitions.
Development of value-added services for pharmacists.
Growth in the specialty pharmaceuticals market.

Threats

Increasing competition from other pharmaceutical distributors and retail pharmacy chains.
Pricing pressures from governments and healthcare providers.
Economic downturn in Europe.
Disruptions in the supply chain.

Competitors & Peers

All American Healthcare Corp — Focuses on the US healthcare market. — (ABCZF)
Anthem Inc — Primarily a health insurance provider. — (ANHGY)
Arches Health Care, Inc. — Unknown differentiation — (ARHCF)
Aspen Healthcare Inc — Unknown differentiation — (ASPHF)
Direct Communication Healthcare — Unknown differentiation — (DCHPF)

Key Metrics

Volume: 0
MoonshotScore: 35/100

Company Profile

CEO: Tilo Köster
Headquarters: Stuttgart, DE
Employees: 26,329
Founded: 2010

AI Insight

AI analysis pending for CAKFY

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does McKesson Europe AG do?

McKesson Europe AG operates in the pharmaceutical distribution and retail pharmacy sectors across Europe. It distributes pharmaceutical products to approximately 40,000 pharmacies and hospitals through its extensive wholesale network. Additionally, it operates around 2,000 retail pharmacies under the Lloyds Pharmacy brand, providing prescription drugs, over-the-counter products, and medical services to individual patients. The company also offers e-commerce and home care services, as well as pharmacy management solutions for pharmacists.

What do analysts say about CAKFY stock?

As of March 16, 2026, a comprehensive analyst consensus for CAKFY is not readily available due to its OTC listing and limited coverage. Key valuation metrics include a negative profit margin of -0.5% and a P/E ratio of -73.27. Growth considerations center on the company's ability to expand its e-commerce and home care services, as well as its strategic partnerships and acquisitions. Investors should conduct their own due diligence and consider the risks associated with investing in OTC stocks.

What are the main risks for CAKFY?

The main risks for McKesson Europe AG include increasing competition in the pharmaceutical distribution and retail pharmacy sectors, pricing pressures from governments and healthcare providers, and potential economic downturns in Europe. Additionally, regulatory changes in the pharmaceutical industry and disruptions in the supply chain could impact the company's operations and profitability. As an OTC-listed company, CAKFY also faces risks related to limited transparency, low liquidity, and potential price volatility.

Is CAKFY a good investment right now?

Use the AI score and analyst targets on this page to evaluate McKesson Europe AG (CAKFY). Our analysis considers fundamentals, technicals, and market sentiment to help you decide.

What is the MoonshotScore for CAKFY?

The MoonshotScore is a proprietary 0-100 AI rating that evaluates McKesson Europe AG across multiple dimensions including financial health, growth trajectory, and risk factors.

Where can I find CAKFY financial statements?

McKesson Europe AG financial data including revenue, earnings, and balance sheet metrics are available in the Financials tab on this page, sourced from institutional-grade data providers.

What do analysts say about CAKFY?

Analyst consensus targets and ratings for McKesson Europe AG are shown in the analysis section. These are aggregated from major Wall Street firms and updated regularly.

How volatile is CAKFY stock?

Check the beta and historical price range on this page to assess McKesson Europe AG's volatility relative to the broader market.